Evaluating the tolerability of the newer mood stabilizers.
Alao
A O
AO
Department of Psychiatry, SUNY Upstate Medical University, New York 13210, USA.
Dewan
M J
MJ
D000085:Acetates / Q000009:adverse effects / Q000627:therapeutic use; D000588:Amines; D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000523:psychology; D002493:Central Nervous System Diseases / Q000139:chemically induced; D003509:Cyclohexanecarboxylic Acids; D004346:Drug Information Services / Q000706:statistics & numerical data; D005632:Fructose / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077206:Gabapentin; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D015994:Incidence; D000077213:Lamotrigine; D001523:Mental Disorders / Q000139:chemically induced; D020258:Neurotoxicity Syndromes / Q000209:etiology; D000077236:Topiramate; D014227:Triazines / Q000009:adverse effects / Q000627:therapeutic use; D014635:Valproic Acid / Q000009:adverse effects / Q000627:therapeutic use; D005680:gamma-Aminobutyric Acid
D000085:Acetates; D000588:Amines; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D014227:Triazines; D000077236:Topiramate; D005632:Fructose; D005680:gamma-Aminobutyric Acid; D014635:Valproic Acid; D000077206:Gabapentin; D000077213:Lamotrigine